Germany's Epigenomics and life science outsourcing firm NextPharma have signed a global manufacturing contract covering Epi proColon, Epigenomics' nucleic acid amplification-based colorectal cancer screening test.
Keeping an eye on growing its global presence and test menu, Genomic Health does not plan to significantly grow its profits in future years, but will instead reinvest that money into research and development efforts.
The merger will give Biosystems International access to MicroBioChips' nanoarray technology and its sales and marketing resources, which are expected to help the company establish new relationships with university-based proteomics laboratories and pharma and biotech firms.
Recently, Mao Mao, a research fellow at Pfizer Oncology Research who is working on several different cancer sequencing projects, spoke to In Sequence about the company's use of sequencing in drug development and the hurdles that still remain in implementing the technology in pharmaceutical research.
GeneNews recently presented a study that found ColonSentry "was able to detect right-sided CRC lesions across all stages with a sensitivity that is at least equal to the detection observed for left-sided lesions."
Enzo has been awarded a license to provide clinical diagnostic services in Pennsylvania, which could help the eventual uptake of ColonSentry, a PCR-based colon cancer risk-stratification test manufactured by Canadian firm GeneNews and for which Enzo has exclusive distribution rights in New York and New Jersey.
While Genomic Health projects "more modest" growth for its legacy node-negative breast cancer business over the next year, newer markets in which the company is still working to secure reimbursement still represent a significant opportunity for expansion in the years ahead.